OMM Newsroom
Kazakhstan plans to produce 494 types of medicine through eight investment projects worth $862 million. Health Minister Akmaral Alnazarova announced the plan on Nov. 3, AnewZ reports, citing local media.
Medicine production and vaccine supply monitoring
The projects will be implemented in stages. Production of the first 300 types of medicine is scheduled to begin between 2027 and 2030. The projects are expected to create more than 1,200 jobs.
Kazakhstan is also introducing a unified digital system to monitor the storage and transportation of vaccines. According to Alnazarova, the system will detect temperature changes in real time, helping preserve vaccine quality and strengthen oversight of immunization programs.
More than 3,500 facilities and 800 vehicles will be connected to the platform. This will make it possible to track temperatures throughout the supply chain, from central distribution warehouses to medical facilities.
Kazakhstan currently spends about 38 billion tenge ($84 million) annually on vaccines and other immunobiological products. The new system is expected to reduce losses and improve inventory management.
Free medicine list to be expanded
The government also plans to expand the range of medicines provided free of charge to outpatients. The updated list is expected to include 22 medicines used to treat 14 diseases.
Kazakhstan has brought forward by three months its procurement process for medicine supplies for 2027. By early October, contracts had been signed for more than 84% of the medicines on the planned procurement list. The figure is expected to reach 95% by the end of the year.
Pharmaceutical plant planned in Almaty
A pharmaceutical plant is also planned in Almaty, with investment of more than 39 billion tenge ($86 million). The project aims to increase domestic medicine production, support local manufacturing of international medicines and lay the groundwork for producing pharmaceutical ingredients in Kazakhstan.
The plant will be developed in stages. From 2030 to 2033, the focus will be on producing finished dosage forms, transferring technologies and establishing capacity for a full production cycle.
The next stage, covering 2034 to 2036, envisages the production of active pharmaceutical ingredients. This is expected to help gradually reduce dependence on imported raw materials.
